Humacyte, Inc. Cost of Revenue
Humacyte, Inc. (HUMA) reported Cost of Revenue of $1.23 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement
us-gaap:CostOfGoodsAndServicesSold · last filed 2026-08-12
- Humacyte, Inc. cost of goods and services sold for the quarter ending 2026-06-30 was $1.23M, a 477.93% increase year-over-year.
- Humacyte, Inc. cost of goods and services sold for the quarter ending 2026-03-31 was $2.04M, a 1286.39% increase year-over-year.
- Humacyte, Inc. cost of goods and services sold for the quarter ending 2025-12-31 was $9.08M.
- Humacyte, Inc. cost of goods and services sold for the quarter ending 2025-09-30 was $260.00K.
- Humacyte, Inc. cost of goods and services sold for fiscal 2025 was $9.70M.
- Humacyte, Inc. cost of goods and services sold for fiscal 2024 was $0.00.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.23M 10-Q · filed 2026-08-12 | $3.27M 10-Q · filed 2026-08-12 | $12.35M derived: sum of 3 quarters · filed 2026-08-12 | $12.61M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $2.04M 10-Q · filed 2026-05-13 | $11.12M derived: sum of 2 quarters · filed 2026-05-13 | $11.38M derived: sum of 3 quarters · filed 2026-05-13 | $11.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $9.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $9.34M derived: sum of 2 quarters · filed 2026-03-27 | $9.55M derived: sum of 3 quarters · filed 2026-08-12 | $9.70M 10-K · filed 2026-03-27 |
| 2025-09-30 | $260.00K 10-Q · filed 2025-11-12 | $473.00K derived: sum of 2 quarters · filed 2026-08-12 | $620.00K 10-Q · filed 2025-11-12 | $620.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $213.00K 10-Q · filed 2026-08-12 | $360.00K 10-Q · filed 2026-08-12 | $360.00K derived: sum of 3 quarters · filed 2026-08-12 | $360.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $147.00K 10-Q · filed 2026-05-13 | $147.00K derived: sum of 2 quarters · filed 2026-05-13 | $147.00K derived: sum of 3 quarters · filed 2026-05-13 | $147.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $0.00 derived: sum of 2 quarters · filed 2026-03-27 | $0.00 derived: sum of 3 quarters · filed 2026-03-27 | $0.00 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $0.00 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-11 | $0.00 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |